| |
| SEPTEMBER 2009 |
|
MKT Explained
Maintaining a suitable temperature in transit is as crucial for pharmaceuticals as it is for food items – a degree too high or low and the product could have a debilitating consumer effect. Wyeth’s Geoffrey Glauser and Norgine’s Nigel Cryer explain the concept of mean kinetic temperature to Nic Paton. view pdf |
The Right Spice
Poised on the cusp of an exciting period of growth, the Indian pharmaceutical market is big and getting bigger, driven by growing prosperity and a shift in disease patterns. Since 2005, a number of intellectual property (IP) and regulatory reforms have unlocked new opportunities for multinational companies. Glenn Snyder, Rob Jacoby and Laveshni Reddy of Deloitte explore the options. view pdf |
Complementary Therapy
Predictions for collaboration between medtech and pharma were overshadowed by the realities of complex relationship boundaries and opposing business models. Now the topic of convergence is set to take centre stage once more on the heels of
a successful two-year study for a pioneering drugeluting peripheral stent created by Cook Medical. Jason Urbanski and Dr Bill Hunter talk to Lorrie Kelly about their success and how they see convergence opportunities evolving over the next few years. view pdf |
Drug Delivery: The Next Decade
How has drug delivery changed during
the first decade of the 21st century
and how is it set to continue? Sven Stegemann of Capsugel examines the discoveries and societal effects that will propel the market onwards from 2010.
view pdf |
The Future of Technology
The market for cancer treatment is expanding as sufferers of the disease grow in number. GlobalData’s Balasubramanyam Nistla examines the main players, key drugs and how generics will change the face of the industry. view pdf |
Crunch Time
The global recession has forced some of the world’s leading companies to reduce their costs through staff reductions and other cost-cutting exercises. Jyoti Ranjan Padhi of analysts GlobalData looks at the effect of this situation on mergers, R&D and financing methods.
view pdf |
Green Pill of Growth
James Hagan of GlaxoSmithKline looks at how the pharmaceutical industry is embracing sustainability, not as an altruistic, socially driven imperative but rather as a new paradigm for all aspects of how the industry conducts business.
view pdf |
The Counterfeit Crisis
In the age of internet connectivity, it is not only online fraudsters putting the public at risk from bogus pharmaceuticals. Colin Mackay of EFPIA looks at how the supply chain needs to be strictly monitored and what technologies should be implemented to give the best results. view pdf |
| |
Rise to the Challenge
Like other markets within the region, growth within the Middle East’s pharmaceutical sector is primarily dependant on oil prices, which have
been incredibly volatile over the past couple of years. There are numerous
factors suggesting a significant growth for this market over the next decade.
GlobalData’s Suraj Ramanathan reports. view pdf |
Remote Control
For a water-tight supply chain, track and trace must begin at the very earliest stages of clinical trials. Frances Penwill-Cook reports.
view pdf |
|
| Special Supplement - Pharmaceutical Outsourcing Decisions |
| CLINICAL TRIALS |
DRUG DELIVERY & DEVELOPMENT |
MANUFACTURING |
New Era of Home Care
Widespread use of electronic health records and new forms of data transmission could link patient care, clinical research and public health, revolutionising the way clinical trials are
conducted. Phin Foster meets Mats Sundgren of AstraZeneca to discuss how such progress could dramatically alter the drug development landscape.
view pdf |
Educate, Innovate
Pharma, academia and biotech – could a balanced mix of the three be the perfect combination for drug discovery? Ray Hill of Imperial College London talks to Steve Coomber about potential pitfalls, culture
clashes and how to deal with fragile relationships between key industry players.
view pdf |
In or Out?
PDA’s Anita Derks and Georg Roessling tell Lorrie Kelly about the pros and cons of contract manufacturing and in-house production when it comes to keeping costs down and getting products onto the market.
view pdf |
| RAW MATERIALS |
|
|
Extra Risk
In the world of pharma ingredients it is most often the extra, non-active parts that create the highest risk to consumer
safety. Dr Arnulf Heubner of the EFCG tells Steve Coomber why regulation needs to focus on the production of excipients to reduce toxicity. view pdf |
|
|
